Filing Details

Accession Number:
0001127602-24-006212
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-21 21:27:09
Reporting Period:
2024-02-16
Accepted Time:
2024-02-21 21:27:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875045 Biogen Inc. BIIB Biological Products, (No Disgnostic Substances) (2836) 330112644
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1769608 Priya Singhal 225 Binney
Cambridge MA 02142
Head Of Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-16 819 $0.00 5,335 No 4 M Direct
Common Stock Disposition 2024-02-16 295 $219.08 5,040 No 4 F Direct
Common Stock Acquisiton 2024-02-16 389 $0.00 5,429 No 4 M Direct
Common Stock Disposition 2024-02-16 173 $219.08 5,256 No 4 F Direct
Common Stock Disposition 2024-02-16 108 $221.49 5,148 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance Stock Unit Disposition 2024-02-16 819 $0.00 819 $0.00
Common Stock Restricted Stock Unit Disposition 2024-02-16 389 $0.00 389 $0.00
Common Stock Restricted Stock Unit Disposition 2024-02-16 485 $0.00 485 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-02-18 2024-02-18 No 4 M Direct
485 2024-02-18 No 4 M Direct
0 2024-02-18 No 4 J Direct
Footnotes
  1. This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
  2. This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.